ClinicalTrials.gg
CompletedNCT05022693Updated Mar 2, 2022

PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

A Phase 1 interventional study of BIO89-100 in NASH - Nonalcoholic Steatohepatitis, sponsored by 89bio, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by 89bio, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
426th of 460
8 · median 56
Started
2021
with 56 others
Phase 1
79 of 547
6 open now
Registered
420th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 426th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 79 in phase 1, and was the 420th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 21 to 65
  • Diagnosis of NASH with compensated cirrhosis by a hepatologist based on Liver Forum criteria.
  • Model for End-Stage Liver Disease (MELD) score \< 12.
  • Child-Turcotte-Pugh (CTP) score \< 7 (Class A).
  • Fibrosis stage F4 by FibroScan.

Key Exclusion Criteria:

  • History of hepatic cirrhosis decompensation, OR overt hepatic encephalopathy OR signs of hepatic cirrhosis decompensation.
  • Prior transjugular intrahepatic portosystemic (TIPS) shunt procedure.
  • known condition other than cirrhosis that may possibly interfere with drug absorption, distribution, metabolism, or excretion.
  • Significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    BIO89-100 30 mg, Open Lable, Single Dose

    Drug: BIO89-100

Interventions

06

What researchers measure

Primary outcomes

  1. PK Profile of liquid formulation of BIO89-100

    Determine maximum observed serum drug concentration (Cmax)

    Time frame: 22 days

  2. PK Profile of liquid formulation of BIO89-100

    Area under the serum drug concentration-by-time curve from time 0 to the time of the last quantifiable drug concentration (AUC0-t)

    Time frame: 22 days

Secondary outcomes

  1. Evaluate the safety and tolerability of the BIO89-100 liquid formulation

    Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) Number of subjects who discontinued due to AEs and due to related AEs

    Time frame: 22 days

07

Study locations

1 site
  • 89bio Clinical Study Site
    Chandler, Arizona 85224, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2021, 4 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2021
First posted
Aug 26, 2021
StartActual
Aug 16, 2021
Primary completionActual
Dec 21, 2021
CompletionActual
Dec 21, 2021
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05022693
Lead sponsor
89bio, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Aug 16, 2021
Primary completion
Dec 21, 2021
Completion
Dec 21, 2021
Last update
Mar 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegozafermin

Start the discussion